KRCA-0008
KRCA-0008 is a selective ALK/Ack1 inhibitor with IC50s of 12 and 4 nM for ALK and Ack1, respectively. KRCA-0008 can be used for the research of cancer[1][2].
Product Specifications
CAS Number
1472795-20-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Ack1; Anaplastic lymphoma kinase (ALK) ; Apoptosis
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/KRCA-0008.html
Purity
96.72
Solubility
DMSO : 230 mg/mL (ultrasonic)
Smiles
ClC1=CN=C(NC2=CC=C(N3CCN(C(C)=O)CC3)C=C2OC)N=C1NC4=CC=C(N5CCN(C(C)=O)CC5)C=C4OC
Molecular Formula
C30H37ClN8O4
Molecular Weight
609.12
Precautions
H302, H315, H319, H335
References & Citations
[1]Park CH, et al. Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. Bioorg Med Chem Lett. 2013 Nov 15;23 (22) :6192-6.|[2]Hwang J, et al. KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth. Invest New Drugs. 2020 Oct;38 (5) :1282-1291.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
15518151 3x 1.0 µg DNA
CD28 CRISPR All-in-one AAV vector set (with saCas9)(Human)
Sign In for Pricing
View Details 
GTR15390074 1 Vial
Lentiviral human SRSF9 sgRNA gene knockout kit - Lentiviral human SRSF9 sgRNA gene knockout kit (plasmid)
Sign In for Pricing
View Details